EU Commission Broadens Melphalan Flufenamide Approval for Multiple Myeloma

The European Commission has expanded the approval for melphalan flufenamide (Pepaxti) in relapsed or refractory multiple myeloma. This decision allows the therapy to be used earlier, moving from fourth-line to third-line treatment and removing a prior requirement for patients to be refractory to three major therapy classes. This broadens treatment options for patients who have received at least two prior lines of treatment.